Zimmer Biomet Holdings Inc. should refund Mexico’s government for more than $2.6m in illicit profits, the Instituto Mexicano del Seguro Social (Mexican Institute of Social Security, or IMSS) alleged in a lawsuit filed on 30 January in an Indiana federal court. IMSS, which provides health care services in Mexico, is suing to recoup what it spent on products made by Zimmer Biomet and its predecessor, Biomet Inc., during what the agency says was a widespread and long-running bribery scheme. Zimmer merged with Biomet in 2015. (Also see "Zimmer, Biomet Sell Off Some U.S. Assets As They Finalize A $14 Bil. Merger" - Medtech Insight, 25 June, 2015.)
Mexico’s Health Care Agency Alleges Zimmer Fraud
Mexico’s health care agency is suing Zimmer Biomet for a refund on purchases it made from the company during a long-running bribery scheme. The agency claims the bribery, which was admitted in a 2017 settlement with the US government, nullified its contracts with the device maker.
More from Latin America
• By
In response to the Trump administration increasing its tariffs on imports from China, Beijing announced a ban on gene sequencers from US biotech firm Illumina, signaling a full-blown trade war could be in the making. Trump also pushed the deadline for implementing tariffs on Canada and Mexico back by another month.
• By
PathAI, a Boston-based AI-pathology startup backed by $355m, partners with Brazil’s largest integrated healthcare network to support diagnosis and treatment of cancer patients using its AISight image management system.
• By
Concerns President Trump’s tariffs could create a full-blown trade war with China jumped dramatically as Beijing responded with its own set of tariffs targeting various US goods. On the medtech front, AdvaMed wants Trump to create a carve-out for Chinese medical devices as he did in his first term.
• By
El Salvador has approved a new law that will establish a new regulatory body responsible for authorizing medicines and setting prices.
More from Geography
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
• By
People living with diabetes who receive continuous glucose monitors (CGMs) through medical supply firms show higher compliance, lower costs of care, and fewer hospitalizations after one year than those who use pharmacies, a new study shows.
• By
Pediatric devices and IVDs are to be a priority. And the European Health Data Space regulation is seen as critical in supporting digital technologies and AI in transforming care.